A benzimidazole derivative, its preparation method and its uses

By designing benzimidazole derivatives to target HIF-1α, the shortcomings of existing HIF-1α inhibitors in the development of anti-tumor drugs have been addressed. Compound 6a exhibits highly efficient anti-proliferative activity and hypoxia selectivity against a variety of tumor cells under hypoxic conditions, with significant in vivo anti-tumor effects, improved platelet aggregation side effects, and good drug-like properties.

CN123106550APending Publication Date: 2026-11-17THE FIRST AFFILIATED HOSPITAL HENGYANG MEDICAL SCHOOL UNIV OF SOUTH CHINA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611317369.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-28
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing HIF-1α inhibitors have problems in the development of anti-tumor drugs, such as insufficient activity, poor specificity, low delivery efficiency, toxic reactions and potential drug resistance mechanisms. No HIF-1α inhibitor has been approved for clinical treatment.

Method used

A series of benzimidazole derivatives were designed and synthesized. Through skeletal transition and structure optimization strategies, HIF-1α was targeted, and a new binding mode was adopted to optimize the structure of compounds 6a-6h, thereby improving antitumor activity, hypoxia selectivity and safety.

Benefits of technology

Compound 6a exhibits highly efficient anti-proliferative activity against various tumor cells under hypoxic conditions, has a clear target binding to HIF-1α, significantly inhibits HIF-1α protein expression, induces oxidative stress and apoptosis in tumor cells, shows significant in vivo anti-tumor effects, improves platelet aggregation side effects, and has good drug-like properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106550A_ABST
    Figure CN123106550A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical preparations and their application technology, specifically relating to a benzimidazole derivative, its preparation method and its use. The structural formula of the benzimidazole derivative is: , , or; wherein R1, R2, R3, R4, R5, R6, R7, R8, and R9 independently represent hydrogen, halogen, C1-3 alkyl or trifluoromethyl, respectively. The compound of this invention is superior in terms of antitumor activity, hypoxia selectivity, target binding specificity and safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical preparations and their application technology, specifically relating to a benzimidazole derivative, its preparation method and its uses. Background Technology

[0002] Malignant tumors are a major disease posing a serious threat to human health, with their incidence and mortality rates showing a continuous upward trend globally. The tumor microenvironment, the internal environment of tumor cells, is highly correlated with the occurrence and development of cancer. Hypoxia is a significant characteristic of the tumor microenvironment. Downstream target genes regulated by the hypoxia-inducible factor HIF-1α are widely involved in multiple aspects of tumor malignant progression and are highly expressed in various solid tumors, closely related to poor patient prognosis. This makes the development of inhibitors targeting HIF-1α-related pathways a hot area of ​​research in anti-tumor drugs.

[0003] YC-1 (rifeciguat) consists of an indazole core, a benzyl side chain, and a furan ring. It is a classic HIF-1α inhibitor with a clear HIF-1α inhibitory mechanism and promising prospects for derivative development. The structural formula of YC-1 is as follows: HIF-1α has relatively low antitumor activity, and most reported compounds suffer from insufficient activity or poor specificity. Currently, no HIF-1α inhibitors have been approved for clinical treatment. This bottleneck may be related to the numerous regulatory pathways of HIF-1α and the potential side effects and safety issues associated with direct inhibition. Most reported HIF-1α inhibitors have limited activity or poor drug-likeness, exhibiting problems such as insufficient specificity, low delivery efficiency, toxic reactions, and potential drug resistance mechanisms. The development of HIF-1α inhibitors faces many challenges, including optimizing compound activity, improving pharmacokinetic properties, and controlling toxic reactions. Summary of the Invention

[0004] The technical problem to be solved by the present invention is to provide a benzimidazole derivative, its preparation method and its use, which has anti-tumor activity, hypoxia selectivity, target binding specificity and safety.

[0005] This invention provides a benzimidazole derivative, the structural formula of which is: , , or ; R1, R2, R3, R4, R5, R6, R7, R8, and R9 represent hydrogen, halogen, C1-3 alkyl, or trifluoromethyl, respectively.

[0006] Preferably, R6, R7, R8, and R9 are H, the halogen is Cl or Br, and the alkyl group is methyl.

[0007] Preferably, R1, R2, R3, R4, and R5 have only one substituent that is halogen, methyl, or trifluoromethyl, and the other substituents are H.

[0008] Preferably, the structural formula of the benzimidazole derivative is: or In this case, R2 is Cl, Br, or methyl, and R1, R3, R4, and R5 are H; or R1 is Br, and R2, R3, R4, and R5 are H.

[0009] Preferably, the structural formula of the benzimidazole derivative is as follows: , or .

[0010] Preferably, the structural formula of the benzimidazole derivative is as follows: , or .

[0011] This invention provides a method for preparing the aforementioned benzimidazole derivative. The preparation method is as follows: A compound having general formula A undergoes a nucleophilic substitution reaction with o-phenylenediamine in the presence of a solvent and an acid-binding agent to yield a compound having general formula C (reaction temperature 50 °C, reaction time 2 h; the solvent is N,N-dimethylformamide; the acid-binding agent is N,N-diisopropylethylamine). A compound having general formula C reacts with cyanogen bromide in a solvent to give a compound having general formula D (reaction temperature: room temperature; reaction time: 6 h; solvent: 95% ethanol). The compound having general formula D reacts with a compound having general formula E in the presence of a solvent and an acid-binding agent to give the above compound (reaction temperature: room temperature; reaction time: 6-8 h; the solvent is anhydrous dichloromethane; the acid-binding agent is a mixture of HATU and triethylamine). The structural formula of the compound of general formula A is The structural formula of the compound with general formula C is The structural formula of the compound with general formula D is The structural formula of the compound with general formula E is: ; The reaction route is as follows: .

[0012] The preparation method is as follows: 1H-benzo[d]imidazolium-2-carboxylic acid reacts with a solvent and an acid-binding agent to form an active ester intermediate B (reaction temperature: room temperature; reaction time: 30 min; solvent: N,N-dimethylformamide; acid-binding agent: a mixture of HATU and triethylamine). The active ester intermediate B reacts with a compound having general formula C in the presence of a solvent to generate a compound having general formula D (reaction temperature: room temperature; reaction time: 4-6 h; the solvent is N,N-dimethylformamide). The compound having general formula D reacts with a compound having general formula E in the presence of a solvent, an acid-binding agent, and a catalyst to yield the above-mentioned compound (reaction temperature: room temperature or 55°C; reaction time: 4-8 h; the solvent is N,N-dimethylformamide; the acid-binding agent is anhydrous potassium carbonate; the catalyst is potassium iodide). The structural formula of active ester intermediate B is as follows: The structural formula of the compound with general formula C is The structural formula of the compound with general formula D is: The structural formula of the compound with general formula E is The reaction route is as follows:

[0013] The preparation method is as follows: Using 3-nitropyridine-2-amine and a compound having general formula B as starting materials, a compound having general formula C was obtained in the presence of a solvent, an acid-binding agent, and a catalyst (reaction temperature: room temperature or 50°C; reaction time: 2 h; the solvent was N,N-dimethylformamide; the acid-binding agent was anhydrous potassium carbonate; the catalyst was potassium iodide). A compound having the general formula C undergoes a reduction reaction in the presence of a solvent and a catalyst to yield a compound having the general formula D (reaction temperature: room temperature or 75°C; reaction time: 2-3 h; solvent: ethanol-water mixture; catalyst: mixture of iron powder and glacial acetic acid). Compounds of general formula D undergo a condensation reaction with 1H-indole-5-carboxaldehyde in the presence of a solvent to give compounds of general formula F (reaction temperature: room temperature or 50°C; reaction time: 4-6 h; the solvent is anhydrous methanol). The above-mentioned compound was obtained by reacting a compound having the general formula F with a solvent and a catalyst (reaction temperature: room temperature or room temperature; reaction time: 6-8 h; the solvent was methanol; the catalyst was sodium metabisulfite). The structural formula of the compound of general formula B is The structural formula of the compound with general formula C is The structural formula of the compound with general formula D is The structural formula of compounds with general formula F is ; The reaction route is as follows: ; The preparation method is as follows: A compound having general formula B undergoes a substitution reaction with 2-nitropyridine-3-amine in the presence of a solvent, an acid-binding agent, and a catalyst to yield a compound having general formula C (reaction temperature is room temperature or 50°C, reaction time is 2 h; the solvent is N,N-dimethylformamide; the acid-binding agent is anhydrous potassium carbonate; the catalyst is potassium iodide). A compound having general formula C undergoes a reduction reaction in the presence of a solvent and a catalyst to yield a compound having general formula D (reaction temperature: room temperature - 75°C, reaction time: 2-3 h; solvent: ethanol-water mixture; catalyst: mixture of iron powder and glacial acetic acid). Compounds of general formula D undergo a condensation reaction with 1H-indole-5-carboxaldehyde in the presence of a solvent to give compounds of general formula F (reaction temperature: room temperature - 50°C, reaction time: 4-6 h; solvent: anhydrous methanol). The above-mentioned compound was obtained by reacting a compound having the general formula F with a solvent and a catalyst (reaction temperature: room temperature to room temperature; reaction time: 6-8 h; the solvent was methanol; the catalyst was sodium metabisulfite). The structural formula of the compound of general formula B is The structural formula of the compound with general formula C is The structural formula of the compound with general formula D is The structural formula of compounds with general formula F is The reaction route is as follows: .

[0014] This invention provides a use of the benzimidazole derivatives, which are used to prepare antitumor drugs.

[0015] Preferably, the tumor is gastric cancer, colon cancer, colorectal cancer, breast cancer, liver cancer, or lung cancer.

[0016] Preferably, the tumor is gastric cancer or colon cancer.

[0017] The beneficial effects of this invention are that, targeting the hypoxia-inducible factor HIF-1α and using the classic HIF-1α inhibitor YC-1 as a lead compound, 15 novel benzimidazole derivatives (Series 1 (compounds 6a-6h) and Series 2 (compounds 13a-13g) were designed and synthesized through skeletal transition and structural optimization strategies. Compared with existing technologies, the compounds of this invention exhibit superior antitumor activity, hypoxia selectivity, target binding specificity, and safety, specifically in the following aspects: 1. Significant in vitro antiproliferative activity and hypoxia selectivity The antiproliferative effects of the compounds of this invention against various tumor cells and normal cells were systematically evaluated using the CCK-8 assay. The results showed that the first series of compounds exhibited excellent antitumor activity under hypoxic conditions, while their activity decreased significantly under normoxic conditions, demonstrating good hypoxia selectivity.

[0018] Among them, compound 6a (N-(1-(4-chlorobenzyl)-1H-benzo[d]imidazol-2-yl)-3-(trifluoromethyl)benzamide) showed the most prominent antitumor activity: under hypoxic (1% O2) conditions, it exhibited the highest half-maximal inhibitory concentration (IC50) against human colon cancer cells HCT-116, human gastric cancer cells HGC-27, and human triple-negative breast cancer cells MDA-MB-231. 50 The effective concentrations were (4.55 ± 0.72) μM, (1.05 ± 0.25) μM, and (2.09 ± 0.03) μM, respectively; the IC50 values ​​for human lung cancer cells A549 and human liver cancer cells HepG-2 were... 50 The IC50 values ​​were (4.31 ± 1.38) μM and (3.18 ± 0.09) μM, respectively. In contrast, under normoxic (21% O2) conditions, compound 6a showed a lower IC50 value for the aforementioned tumor cells. 50 All values ​​were greater than 100 μM or significantly increased, indicating that it has a highly selective killing effect on the hypoxic tumor microenvironment.

[0019] Compounds 6b and 6c showed effects on the IC50 expression of HCT-116 cells under hypoxic conditions. 50 The concentrations were (8.16 ± 1.65) μM and (8.76 ± 1.66) μM, respectively, also exhibiting clear hypoxia-dependent antiproliferative activity. The overall activity of the second series of compounds (13a-13g) was weaker than that of the first series, but compounds 13d, 13e, and 13g still showed some inhibitory effect on HCT-116 cells under hypoxic conditions (IC50). 50 The values ​​were 40.51 ± 3.71 μM, 49.74 ± 5.84 μM, and 36.54 ± 2.57 μM, respectively, providing a reference for subsequent structural optimization.

[0020] 2. Safety window for normal cells Cytotoxicity assays showed that compound 6a had an IC50 inhibitory effect on normal human colonic epithelial cells NCM-460, normal human gastric mucosal epithelial cells GES-1, and normal human mammary epithelial cells MCF-10A. 50 The effective values ​​were (14.96 ± 1.37) μM, (39.29 ± 5.82) μM, and greater than 100 μM, respectively, which were significantly higher than their IC50 values ​​against most tumor cells. 50 The values ​​indicate that the compounds of this invention exhibit good tumor-selective toxicity and a wide safety window. In contrast, the positive control drug YC-1 showed a lower IC50 value on GES-1 cells. 50 The concentration was (12.75 ± 3.64) μM, indicating strong normal cytotoxicity.

[0021] 3. Clear HIF-1α target binding and novel mechanism of action Mechanistic studies revealed that compound 6a can directly bind to the HIF-1α protein. Cellular thermal migration assays (CETSA) showed that binding of 6a to HIF-1α significantly improved its thermal stability, increasing the melting temperature (Tm) by approximately 6–8 °C, confirming a direct interaction between the two. Molecular docking results showed that 6a stably binds to the hydrophobic pocket of HIF-1α (located at the interface between the α and β chains), forming novel binding modes through hydrogen bonds (with LYS155), p-π interactions (with HIP166), and electrostatic / hydrophobic interactions (with LEU169, GLU170, HIP199, and VAL221).

[0022] Western blot experiments further confirmed that compound 6a can inhibit hypoxia-induced HIF-1α protein accumulation in a concentration-dependent manner, effectively antagonize the overexpression of HIF-1α under hypoxic conditions, and thus block its downstream pro-tumor signaling pathways.

[0023] 4. Inducing oxidative stress and apoptosis in tumor cells Reactive oxygen species (ROS) assays showed that compound 6a significantly increased intracellular ROS levels in MDA-MB-231 cells in a concentration-dependent manner. Flow cytometry analysis revealed that 6a promoted tumor cell apoptosis in a concentration-dependent manner. These results indicate that the compounds of this invention exert antitumor effects by activating oxidative stress pathways and inducing apoptosis.

[0024] 5. Excellent in vivo antitumor activity In the MDA-MB-231 xenograft nude mouse model, compound 6a (20 mg / kg, intraperitoneal injection, every 2 days for 14 consecutive days) showed significant in vivo antitumor effects, with a tumor inhibition rate of 55.4%, and significantly inhibited tumor growth. During the administration period, no significant decrease in body weight was observed in the experimental animals, and no obvious toxic reactions were observed, indicating that compound 6a has good in vivo tolerability and safety.

[0025] 6. Improves platelet aggregation side effects Platelet aggregation inhibition assays showed that compound 6a exhibited significantly weaker inhibitory effects on platelet aggregation compared to the positive control drug YC-1. YC-1, a compound known to possess strong platelet aggregation inhibitory activity, has its clinical application limited by side effects such as bleeding risk; while 6a, while retaining excellent antitumor activity, significantly improves this safety deficiency and possesses greater potential for drug development.

[0026] 7. Good drug-like properties The physicochemical properties of compound 6a were predicted using computer-aided drug design methods. The results showed that it has 1 hydrogen bond donor, 5 hydrogen bond acceptors, 6 rotatable bonds, a lipid-water partition coefficient (CLogP) of 5.11, a topological polar surface area (TPSA) of 46.92 Ų, and a molecular weight of 429.8. These parameters largely meet the requirements of the Lipinski class of drugs, indicating that compound 6a possesses good membrane permeation potential and oral absorption prospects.

[0027] In summary, the benzimidazole derivatives provided by this invention, particularly compound 6a, exhibit highly efficient and selective antiproliferative activity against various solid tumor cells under hypoxic conditions by directly targeting HIF-1α and employing a novel binding mode. They demonstrate significant in vivo antitumor effects while exhibiting low cytotoxicity to normal cells and significantly improving the platelet aggregation inhibition side effect of the lead compound YC-1. This invention provides important candidate compounds and technical insights for the development of novel antitumor drugs targeting HIF-1α. Attached Figure Description

[0028] Figure 1 The results show the inhibition of compound 6a plate clones. (A) Effects of compound 6a and positive control YC-1 on MDA-MB-231 plate clones under hypoxic conditions. (B) Quantitative column analysis of the effects of compound 6a and positive control YC-1 on MDA-MB-231 plate clones. Compared with the control group, "***" indicates p<0.001, "****" indicates p <0.0001.

[0029] Figure 2The effect of compound 6a on the migration ability of MDA-MB-231 cells. (A) The degree of inhibition of cell migration by different concentrations of compound 6a on MDA-MB-231 cells under hypoxic conditions. (B) Bar chart of cell migration rate. Each experiment was independently repeated three times. Compared with the hypoxic control group, "*" indicates... p <0.05, "**" indicates p <0.01.

[0030] Figure 3 The results show the binding ability of the compound in Example 1 to HIF-1α and its effect on protein stability. Figure 3 (A) HIF-1α protein expression level after gradient heating. (B) Melting curve after gradient heating. Each experiment was independently repeated three times. (C) The degree of inhibition of HIF-1α protein expression by different concentrations of compound 6a after treatment of MDA-MB-231. (D) Protein expression level in each group compared with the hypoxia control group. Each experiment was independently repeated three times. Compared with the hypoxia control group, "***" indicates... p <0.001, "****" indicates p <0.0001.

[0031] Figure 4 The effect of compound 6a on ROS levels in MDA-MB-231 cells.

[0032] Figure 5 The effect of the compound in Example 1 on cell apoptosis. Figure 5 (A) Effect of compound 6a on apoptosis levels in MDA-MB-231 cells. (B) Bar chart of apoptosis rate. Each experiment was independently repeated three times. Compared with the hypoxia control group, "**" indicates... p <0.01, "***" indicates p <0.001.

[0033] Figure 6 To demonstrate the in vivo antitumor activity of compound 6a against MDA-MB-231 cells. (A) Tumor volume. (B) Nude mouse body weight. (C) Tumor image. (D) Tumor weight. Data are expressed as mean ± SD (n=5). Compared with group YC-1, "#" indicates... p <0.05; compared with the control group, "**" indicates p <0.01, "****" indicates p <0.0001.

[0034] Figure 7The effects of compound 6a and the positive control drug YC-1 on platelet aggregation function. (A) Heatmap analysis of the inhibition rates of compound 6a and YC-1 / comparison of the inhibitory activities of the compounds at different concentrations; (B) Concentration-dependent curves of platelet aggregation inhibition rates of compound 6a and YC-1.

[0035] Figure 8 This is a three-dimensional interaction diagram between compound 6a and HIF-1α.

[0036] Figure 9 This is a two-dimensional interaction diagram between compound 6a and HIF-1α. Detailed Implementation

[0037] Example 1 N -(1-(4-chlorobenzyl)-1 H -benzo[ d Preparation of imidazole-2-yl)-3-(trifluoromethyl)benzamide (6a) Weigh 1.2 g of o-phenylenediamine into a 100 mL round-bottom flask and add... N , N Dissolve 5 mL of dimethylformamide (DMF) and slowly add it dropwise to the reaction system. N , N Diisopropylethylamine (DIPEA, 1.5 mL) was added dropwise, and the mixture was stirred for 5 min afterward to ensure homogeneity. The mixture was then placed in a water bath at 50 °C and stirred continuously. Separately, 1.0 g of p-bromomethyl-4-chlorobenzene was dissolved in 2 mL of DMF and slowly added dropwise to the reaction system through a constant-pressure dropping funnel. After the addition was complete, the mixture was stirred at 50 °C for 2 h. After the reaction was complete, the mixture was diluted with 30 mL of distilled water, extracted three times with ethyl acetate, and the organic phases were combined. The mixture was dried over anhydrous sodium sulfate, allowed to stand for 20 min, and then filtered under reduced pressure to remove the drying agent. The filtrate was collected, and an appropriate amount of silica gel powder was added. The mixture was then rotary evaporated at 40 °C to obtain the crude product loaded on silica gel. The crude product was purified by silica gel column chromatography using dichloromethane as the eluent. The target fraction was collected to obtain the intermediate product. N 1-(4-chlorobenzyl)phenyl-1,2-diamine, yield 86%.

[0038] Weigh N 1-(4-chlorobenzyl)phenyl-1,2-diamine (2.3 g) was placed in a 50 mL round-bottom flask and dissolved in 10 mL of 95% ethanol. Cyanide (1.3 g) was slowly added under stirring at room temperature, and the reaction was continued with stirring at room temperature for 6 h.

[0039] The above reaction solution was transferred to a 50 mL round-bottom flask. 2.3 g of 3-(trifluoromethyl)benzoic acid was weighed and dissolved in 10 mL of anhydrous dichloromethane. Then, HATU and triethylamine (2.8 mL) were added sequentially to the reaction system, and the mixture was stirred at room temperature for 6–8 h. After the reaction was complete, the mixture was washed with 30 mL of saturated brine, shaken thoroughly, and allowed to stand for separation. The lower organic phase was collected, dried over anhydrous sodium sulfate, and allowed to stand for 10 min. The desiccant was removed by vacuum filtration, and the filtrate was collected. The crude product, a pale yellow oil, was obtained by rotary evaporation below 35 °C. The crude product was purified by silica gel column chromatography to obtain the target compound. N -(1-(4-chlorobenzyl)-1 H -benzo[ d Imidazol-2-yl)-3-(trifluoromethyl)benzamide (6a) is a white powdery solid with a yield of 72%. The structural formula of compound 6a is: .

[0040] The relevant data is as follows: mp: 220-221 ℃; 1 H NMR (500 MHz, DMSO- d 6) δ 9.35 (s, 1H), 8.52 (d, J = 7.8 Hz, 1H), 8.47 (s, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.73 (t, J =7.7 Hz, 1H), 7.57 (dd, J = 6.3, 2.6 Hz, 1H), 7.51 (dd, J = 6.1, 2.8 Hz, 1H), 7.47 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 7.28 – 7.22 (m, 2H), 5.53(s, 2H). 13 C NMR (126 MHz, DMSO- d 6) δ 171.51, 152.00, 138.80, 135.51, 132.41,132.08, 129.25, 129.19 – 128.63, 128.49, 127.32, 125.07, 124.71, 122.83,112.13, 109.74, 48.35, 44.02. ESI-HRMS: m / zcalcd. for C 22 H 15 ClF3N3O [M+H] + :430.0934, found 430.0936.

[0041] Example 2 N -(1-(4-bromobenzyl)-1 H -benzo[ d Preparation of imidazole-2-yl)-3-(trifluoromethyl)benzamide (6b) The following preparation was made according to the method of Example 1, using 1-bromomethyl-4-bromobenzene instead of 1-bromomethyl-4-chlorobenzene. N -(1-(4-bromobenzyl)-1 H -benzo[ d [Imidazol-2-yl)-3-(trifluoromethyl)benzamide, yield approximately 80%. The structural formula of compound 6b is: .

[0042] The relevant data is as follows: mp: 225-226 ℃; 1 H NMR (500 MHz, DMSO- d 6) δ 12.91 (s, 1H), 8.52 (d, J = 7.8 Hz, 1H), 8.46 (s, 1H), 7.89 (d, J = 7.7 Hz, 1H), 7.73 (d, J =7.7 Hz, 1H), 7.56 (dd, J = 12.9, 7.5 Hz, 2H), 7.53 – 7.49 (m, 2H), 7.39 (d, J =8.3 Hz, 2H), 7.27 – 7.21 (m, 2H), 5.51 (s, 2H). 13 C NMR (126 MHz, DMSO- d 6) δ 171.68, 152.17, 138.97, 136.09, 132.58, 131.54, 129.73, 129.54 – 129.41,129.41 – 128.78, 127.49, 124.85, 122.97, 120.76, 112.30, 109.90, 44.25. ESI-HRMS: m / zcalcd. for C 22 H 15 BrF3N3O [M+H] + : 474.0429, found 474.0426.

[0043] Example 3 N -(1-(4-methylbenzyl)-1 H -benzo[ d Preparation of imidazole-2-yl)-3-(trifluoromethyl)benzamide (6c) The following preparation was made according to the method of Example 1, using 1-bromomethyl-4-methylbenzene instead of 1-bromomethyl-4-chlorobenzene. N -(1-(4-methylbenzyl)-1 H -benzo[ d [Imidazol-2-yl)-3-(trifluoromethyl)benzamide, yield 73%. The structural formula of compound 6c is: .

[0044] The relevant data is as follows: mp: 198-200 ℃; 1 H NMR (500 MHz, DMSO- d 6) δ 12.88 (s, 1H),8.58 – 8.47 (m, 2H), 7.89 (d, J = 7.7 Hz, 1H), 7.73 (t, J = 7.7 Hz, 1H), 7.53(ddd, J = 31.0, 5.8, 3.1 Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 7.26 – 7.19 (m,2H), 7.13 (d, J = 7.8 Hz, 2H), 5.47 (s, 2H), 2.23 (s, 3H). 13 C NMR (126 MHz, DMSO- d 6) δ 171.47, 151.99, 138.90, 136.72, 133.43, 132.38, 129.19, 129.00,128.99 – 128.58, 127.35, 124.70, 122.71, 112.06, 109.85, 48.36, 44.50, 20.40.ESI-HRMS: m / zcalcd. for C 23 H 18 F3N3O [M+H] + : 410.1480, found 410.1484.

[0045] Example 4 N -(1-(3-bromobenzyl)-1 H -benzo[ d Preparation of imidazole-2-yl)-3-(trifluoromethyl)benzamide (6d) The following preparation was made according to the method of Example 1, using 1-bromomethyl-3-bromobenzene instead of 1-bromomethyl-4-chlorobenzene. N -(1-(3-bromobenzyl)-1 H -benzo[ d [Imidazol-2-yl)-3-(trifluoromethyl)benzamide, yield 82%. The structural formula of compound 6d is: .

[0046] The relevant data is as follows: mp: 223-225 ℃; 1 H NMR (500 MHz, DMSO- d 6) δ 12.92 (s, 1H),8.57 – 8.45 (m, 2H), 7.89 (d, J = 7.4 Hz, 1H), 7.73 (s, 2H), 7.57 (dd, J = 8.0, 4.8 Hz, 2H), 7.45 (dd, J = 31.1, 7.6 Hz, 2H), 7.34 – 7.21 (m, 3H), 5.53 (s, 2H). 13 C NMR (126 MHz, DMSO- d 6) δ 171.75, 152.26, 139.46, 139.02, 132.66, 130.94,130.59, 129.44, 128.98, 127.61, 126.66, 124.95, 123.12, 121.83, 112.41,109.97, 44.33. ESI-HRMS: m / z calcd. for C 22 H 15 BrF3N3O [M+H] +: 474.0429, found474.0432.

[0047] Example 5 1-(4-chlorobenzyl)- N -(3-(trifluoromethyl)phenyl)-1 H Preparation of benzo[d]imidazol-2-carboxamide (6e) Weigh 1 H -benzo[ d Imidazole-2-carboxylic acid (1.6 g) was placed in a 50 mL round-bottom flask and dissolved in DMF (5 mL). HATU and triethylamine (2.8 mL) were added sequentially to the reaction system. The mixture was stirred and activated at room temperature for 30 min. After activation, 3-(trifluoromethyl)aniline (1.5 mL) was added, and the reaction was continued at room temperature with stirring for 4–6 h. After the reaction was complete, ethyl acetate (20 mL) was added for dilution, and the mixture was washed three times with saturated brine (15 mL). The upper organic phase was collected. Anhydrous sodium sulfate was added to the organic phase for drying. After standing for 10 min, the drying agent was removed by suction filtration, and the filtrate was collected and evaporated to dryness below 40 °C to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain an intermediate. N -(3-(trifluoromethyl)phenyl)-1 H -benzo[ d Imidazole-2-carboxamide.

[0048] Weigh N -(3-(trifluoromethyl)phenyl)-1 H -benzo[ d Imidazole-2-carboxamide (3.2 g) was placed in a 50 mL round-bottom flask and dissolved in DMF (5 mL). 1-Bromomethyl-4-chlorobenzene (2.5 g), anhydrous potassium carbonate (2.8 g), and potassium iodide (0.17 g) were added sequentially to the reaction system. The mixture was stirred at room temperature for approximately 4-6 hours until the reaction was complete. A 100 mL beaker containing 20 mL of ice water was poured slowly into the beaker while stirring, resulting in the gradual precipitation of a pale yellow solid. The mixture was transferred to a 250 mL separatory funnel and extracted three times with ethyl acetate (15 mL). The organic phases were combined and washed three times with saturated brine (10 mL) to remove residual DMF and salts. The mixture was dried over anhydrous sodium sulfate, allowed to stand for 10 min, and then filtered. The filtrate was collected and concentrated by rotary evaporation below 40 °C to obtain a pale yellow oily crude product. The crude product was purified by silica gel column chromatography to obtain the target compound 1-(4-chlorobenzyl)- N -(3-(trifluoromethyl)phenyl)-1 H 6e is a white solid, produced in 68% yield. The structural formula of compound 6e is: .

[0049] The relevant data is as follows: mp: 155-156 ℃; 1 H NMR (500 MHz, DMSO- d 6) δ 11.36 (s, 1H),8.39 (s, 1H), 8.15 (d, J = 8.3 Hz, 1H), 7.87 (d, J = 7.5 Hz, 1H), 7.71 (d, J =7.9 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 7.7 Hz, 1H), 7.39 (dd, J =15.3, 8.7 Hz, 4H), 7.28 (d, J = 8.4 Hz, 2H), 6.00 (s, 2H). 13 C NMR (126 MHz, DMSO- d 6) δ 158.45, 143.16, 140.90, 139.14, 136.42, 132.31, 130.11, 129.71,129.46, 128.99, 128.83, 125.34, 124.44, 123.90, 123.20, 120.73, 116.90,112.05, 48.79, 47.45. ESI-HRMS: m / z calcd. for C 22 H 15 ClF3N3O [M+H] + : 430.0934, found 430.0936.

[0050] Example 6 1-(4-Bromobenzyl)- N -(3-(trifluoromethyl)phenyl)-1 H -benzo[ d Preparation of imidazole-2-carboxamide (6f) 1-(4-bromobenzyl)- was prepared according to the method of Example 5, replacing 1-bromomethyl-4-bromobenzene. N -(3-(trifluoromethyl)phenyl)-1 H -benzo[ dImidazole-2-carboxamide, yield 66%. The structural formula of compound 6f is: .

[0051] The relevant data is as follows: mp: 157-158 ℃; 1 H NMR (500 MHz, CDCl3- d 6) δ 9.78 (s, 1H),8.07 (s, 1H), 7.89 – 7.80 (m, 2H), 7.49 (t, J = 7.9 Hz, 1H), 7.42 – 7.37 (m,6H), 7.11 (d, J = 8.4 Hz, 2H), 5.98 (s, 2H). 13 C NMR (126 MHz, DMSO- d 6) δ 158.26,142.98, 140.72, 138.96, 136.70, 136.20, 131.56, 129.92, 129.53, 129.28,129.12, 125.12, 124.26, 123.72, 123.02, 120.59, 116.72, 111.86, 47.33. ESI-HRMS: m / z calcd. for C 22 H 15 BrF3N3O [M+H] + : 474.0429, found 474.0431.

[0052] Example 7 1-(4-methylbenzyl)- N -(3-(trifluoromethyl)phenyl)-1 H -benzo[ d Preparation of imidazole-2-carboxamide (6g) 1-(4-methylbenzyl)- was prepared according to the method of Example 5, replacing 1-bromomethyl-4-methylbenzene. N -(3-(trifluoromethyl)phenyl)-1 H -benzo[ d Imidazole-2-carboxamide, yield 69%. The structural formula of 6g of compound is: .

[0053] The relevant data is as follows: mp: 146-147 ℃;1 H NMR (500 MHz, CDCl3- d 6) δ 9.83 (s, 1H),8.10 (s, 1H), 7.93 – 7.79 (m, 2H), 7.49 (d, J = 8.0 Hz, 1H), 7.47 – 7.44 (m,1H), 7.42 (d, J = 7.8 Hz, 1H), 7.38 (dd, J = 6.2, 3.2 Hz, 2H), 7.15 (d, J = 8.1Hz, 2H), 7.10 (d, J = 8.0 Hz, 2H), 6.02 (s, 2H), 2.29 (s, 3H). 13 C NMR (126 MHz, DMSO- d 6) δ 158.37, 143.03, 140.73, 139.01, 136.74, 136.26, 134.23, 129.94,129.55, 129.24, 126.90, 125.20, 124.96, 124.23, 123.59, 123.03, 120.53,116.68, 112.02, 47.61, 20.62. ESI-HRMS: m / z calcd. for C 23 H 18 F3N3O [M+H] + :410.1480, found 410.1483.

[0054] Example 8 1-(3-bromobenzyl)- N -(3-(trifluoromethyl)phenyl)-1 H -benzo[ d Preparation of imidazole-2-carboxamide (6h) 1-(3-bromobenzyl)- was prepared according to the method of Example 5, replacing 1-bromomethyl-3-bromobenzene. N -(3-(trifluoromethyl)phenyl)-1 H -benzo[ d Imidazole-2-carboxamide, yield 85%. The structural formula of compound 6h is: .

[0055] The relevant data is as follows: mp: 175-176 ℃; 1 H NMR (500 MHz, CDCl3- d 6) δ 9.81 (s, 1H),8.09 (s, 1H), 7.93 – 7.83 (m, 2H), 7.51 (t, J = 8.0 Hz, 1H), 7.41 (dd, J =12.3, 9.4 Hz, 6H), 7.21 – 7.12 (m, 2H), 6.03 (s, 2H). 13 C NMR (126 MHz, DMSO- d 6) δ 158.27, 143.08, 140.71, 140.01, 138.94, 136.19, 130.90, 130.41, 129.94,129.58, 129.29, 125.83, 125.19, 124.27, 123.77, 123.02, 121.84, 120.58,116.75, 111.83, 47.26. ESI-HRMS: m / z calcd. for C 22 H 15 BrF3N3O [M+H] + : 474.0429, found 474.0432.

[0056] Example 9 3-(4-chlorobenzyl)-2-(1 H -indol-5-yl)-3 H -imidazo[4,5- b Preparation of pyridine (13a) Weigh 1.4 g of 3-nitropyridine-2-amine into a 50 mL round-bottom flask, add 5 mL of DMF to dissolve it, and then add 2.5 g of 1-bromomethyl-4-chlorobenzene, 2.8 g of anhydrous potassium carbonate, and 0.17 g of potassium iodide in sequence. Heat and stir the mixture in a constant temperature oil bath at 50 °C for 2 h. After the reaction is complete, cool it to room temperature and slowly pour it into a 100 mL beaker containing 20 mL of ice water while stirring. A pale yellow solid can be seen precipitating out. The mixture was extracted three times with ethyl acetate (15 mL), the organic phases were combined, washed twice with saturated brine (15 mL), dried with anhydrous sodium sulfate, allowed to stand for 20 min, filtered and collected the filtrate, concentrated by rotary evaporation below 40 °C to obtain a yellow oily crude product, dissolved in an ethanol-water mixture (10 mL, ethanol / water = 4:1, v / v), then iron powder (1.7 g) and glacial acetic acid (5 mL) were added, and the mixture was heated and stirred in a constant temperature oil bath at 75 °C for 2-3 h. After cooling to room temperature, the filtrate was obtained by vacuum filtration through a Buchner funnel, concentrated by rotary evaporation, adjusted to neutral with saturated sodium bicarbonate solution, extracted three times with ethyl acetate (15 mL), the organic layers were combined, dehydrated with anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was separated by silica gel column chromatography and concentrated under reduced pressure to obtain a white intermediate.

[0057] Weigh out the above intermediate (2.5 g) and 1 H Indole-5-carboxaldehyde (1.4 g) was placed in a 50 mL round-bottom flask and dissolved in anhydrous methanol (10 mL). The mixture was heated and stirred in a 50 °C water bath for 4-6 h until the reaction was terminated. After cooling to room temperature, the mixture was concentrated by rotary evaporation below 40 °C to obtain a crude yellow oily imine intermediate. The crude product was dissolved in methanol (10 mL). Sodium metabisulfite (2.9 g) was added to the reaction system and the mixture was stirred at room temperature for 6-8 h. After the reaction was completed, the reaction solution was concentrated by rotary evaporation below 40 °C to obtain the crude product. The crude product was purified by silica gel column chromatography and concentrated to dryness to obtain the target compound 3-(4-chlorobenzyl)-2-(1 H -indol-5-yl)-3 H -imidazo[4,5- b Pyridine is an off-white solid with a yield of 75%. The structural formula of compound 13a is: .

[0058] The relevant data is as follows: mp: 243-244 ℃; 1 H NMR (500 MHz, DMSO- d 6) δ 11.43 (s, 1H), 8.34 (dd, J= 4.8, 1.4 Hz, 1H), 8.12 (dd, J = 8.0, 1.4 Hz, 1H), 7.99 – 7.91 (m,1H), 7.54 (d, J = 8.5 Hz, 1H), 7.52 – 7.43 (m, 2H), 7.38 – 7.29 (m, 3H), 7.05(d, J = 8.5 Hz, 2H), 6.52 (dd, J = 2.5, 1.7 Hz, 1H), 5.66 (s, 2H). 13 C NMR (126MHz, DMSO- d 6) δ 155.55, 148.35, 143.10, 136.43, 136.07, 134.35, 131.70, 128.42,127.95, 127.27, 126.71, 126.19, 121.62, 121.12, 119.83, 118.50, 111.62,101.77, 45.49. ESI-HRMS: m / z calcd. for C 21 H 15 ClN4[M+H] + : 359.1063, found359.1063.

[0059] Example 10 3-(4-bromobenzyl)-2-(1 H -indol-5-yl)-3 H -imidazo[4,5- b Preparation of pyridine (13b) 3-(4-bromobenzyl)-2-(1-bromomethyl-4-chlorobenzene) was prepared according to the method of Example 9, instead of 1-bromomethyl-4-bromobenzene. H -indol-5-yl)-3 H -imidazo[4,5- b Pyridine, yield 87%. The structural formula of compound 13b is: .

[0060] The relevant data is as follows: mp: 235-236 ℃; 1 H NMR (500 MHz, DMSO- d 6) δ 11.41 (s, 1H), 8.31 (dd,J = 4.8, 1.4 Hz, 1H), 8.10 (dd, J = 8.0, 1.4 Hz, 1H), 7.93 (s, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7.48 – 7.40 (m, 4H), 7.32 (dd, J = 8.0, 4.8 Hz, 1H), 6.96 (d, J = 8.5 Hz, 2H), 6.52 – 6.47 (m, 1H), 5.61 (s, 2H). 13 C NMR (126 MHz, DMSO- d 6) δ 155.79, 148.55, 143.32, 136.68, 134.59, 131.55, 128.48, 127.49,126.94, 126.43, 121.83, 121.34, 120.44, 120.04, 118.74, 111.85, 102.01,45.76. ESI-HRMS: m / z calcd. for C 21 H 15 BrN4[M+H] + : 403.0558, found 403.0560.

[0061] Example 11 3-(4-methylbenzyl)-2-(1 H -indol-5-yl)-3 H -imidazo[4,5- b Preparation of pyridine (13c) 3-(4-methylbenzyl)-2-(1-bromomethyl-4-chlorobenzene) was prepared according to the method of Example 9, instead of 1-bromomethyl-4-methylbenzene. H -indol-5-yl)-3 H -imidazo[4,5- b Pyridine, yield 69%. The structural formula of compound 13c is: .

[0062] The relevant data is as follows: mp: 241-242 ℃; 1 H NMR (500 MHz, DMSO- d 6) δ 11.41 (s, 1H), 8.33 (dd,J = 4.7, 1.1 Hz, 1H), 8.10 (dd, J = 7.9, 1.1 Hz, 1H), 7.97 (s, 1H), 7.52 (s, 2H), 7.46 (t, J = 2.6 Hz, 1H), 7.32 (dd, J = 7.9, 4.8 Hz, 1H), 7.05(d, J = 7.9 Hz, 2H), 6.91 (d, J = 7.9 Hz, 2H), 6.50 (s, 1H), 5.62 (s, 2H), 2.21(s, 3H). 13 C NMR (126 MHz, DMSO- d 6) δ 155.36, 148.32, 142.64, 136.12, 135.96,134.30, 133.89, 128.69, 126.99, 126.37, 125.79, 121.44, 120.85, 119.95,117.99, 111.25, 101.45, 45.54, 20.09. ESI-HRMS: m / z calcd. for C 22 H 18 N4[M+H] + :339.1610, found 339.1614.

[0063] Example 12 3-(4-trifluoromethylbenzyl)-2-(1 H -indol-5-yl)-3 H -imidazo[4,5- b Preparation of pyridine (13d) 3-(4-trifluoromethylbenzyl)-2-(1-bromomethyl-4-chlorobenzene) was prepared according to the method of Example 9, replacing 1-bromomethyl-4-trifluoromethylbenzene. H -indol-5-yl)-3 H -imidazo[4,5- b Pyridine, yield 77%. The structural formula of compound 13d is: .

[0064] The relevant data is as follows: mp: 249-250 ℃; 1 H NMR (500 MHz, DMSO-d 6) δ 11.45 (s, 1H), 8.35 (dd, J = 4.8, 1.4 Hz, 1H), 8.14 (dd, J = 8.0, 1.4 Hz, 1H), 7.96 (s, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7.48 (ddt, J = 6.3, 4.4, 2.0 Hz, 4H), 7.36 (dd, J =8.0, 4.8 Hz, 1H), 7.00 (d, J = 8.5 Hz, 2H), 6.60 – 6.47 (m, 1H), 5.65 (s, 2H). 13 C NMR (126 MHz, DMSO- d 6) δ 155.78, 148.55, 143.48, 136.75, 134.37, 131.63,128.59, 127.55, 127.05, 126.39, 121.90, 121.45, 120.52, 119.91, 118.87,111.93, 102.07, 45.87. ESI-HRMS: m / z calcd. for C 22 H 15 F3N4[M+H] + : 393.1327, found 393.1328.

[0065] Example 13 1-(4-chlorobenzyl)-2-(1 H -indol-5-yl)-1 H -imidazo[4,5- b Preparation of pyridine (13e) Weigh 1.4 g of 2-nitropyridine-3-amine (7) into a 50 mL round-bottom flask, add 5 mL of DMF to dissolve it, and then add 2.5 g of 1-bromomethyl-4-chlorobenzene (8), 2.8 g of anhydrous potassium carbonate, and 0.17 g of potassium iodide in sequence. Heat and stir in an oil bath at 50 °C. After reacting for 2 h, cool the reaction solution to room temperature and slowly pour it into a 100 mL beaker containing 20 mL of ice water while stirring. Extract the mixture three times with 15 mL of ethyl acetate. Combine the organic phases, wash with 15 mL of saturated brine, dry with anhydrous sodium sulfate, let stand for 20 min, filter, collect the filtrate, and concentrate by rotary evaporation to obtain the crude product. The crude product was dissolved in an ethanol-water mixture (10 mL, v / v = 4:1), and iron powder (3.0 mmol) and glacial acetic acid (0.5 mL) were added. The mixture was heated to 75 °C and stirred for 2–3 h. The reaction solution was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The solution was adjusted to neutral with saturated sodium bicarbonate solution and extracted three times with ethyl acetate (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography to obtain the intermediate. N 3-(4-Chlorobenzyl)pyridine-2,3-diamine is an off-white solid with a yield of 81%.

[0066] Weigh N 3-(4-chlorobenzyl)pyridine-2,3-diamine (2.5 g) and 1 H Indole-5-carboxaldehyde (1.4 g) was placed in a 50 mL round-bottom flask and dissolved in anhydrous methanol (10 mL). The mixture was heated and stirred in a 50 °C water bath for 4-6 h. The reaction mixture was then removed from the water bath, cooled to room temperature, and concentrated by rotary evaporation below 40 °C to obtain a crude imine intermediate. This intermediate was dissolved in methanol (10 mL), and sodium metabisulfite (2.9 g) was added to the reaction system. The mixture was stirred at room temperature for 6-8 h. After the reaction was complete, the mixture was concentrated by rotary evaporation below 40 °C to obtain a pale yellow oily crude product. The crude product was purified and concentrated by silica gel column chromatography to obtain the target compound 1-(4-chlorobenzyl)-2-(1 H -indol-5-yl)-1 H -imidazo[4,5- b Pyridine is an off-white solid with a yield of 79%. The structural formula of compound 13e is: .

[0067] The relevant data is as follows: mp: 255-256 ℃; 1 H NMR (500 MHz, DMSO- d 6) δ11.44 (s, 1H), 8.43 (dd, J = 4.8, 1.4 Hz, 1H), 7.97 (d, J = 0.7 Hz, 1H), 7.87 (dd, J = 8.0, 1.5Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.53 – 7.43 (m, 2H), 7.39 – 7.30 (m, 2H), 7.24 (dd, J = 8.0, 4.8 Hz, 1H), 7.04 (d, J = 8.5 Hz, 2H), 6.55 (dd, J = 2.5, 1.6Hz, 1H), 5.66 (s, 2H). 13 C NMR (126 MHz, DMSO- d 6) δ 157.23, 155.21, 144.16,136.65, 135.64, 132.14, 128.79, 128.11, 127.50, 126.95, 122.08, 121.57,119.70, 119.01, 117.72, 111.88, 102.02, 47.13. ESI-HRMS: m / z calcd. forC 21 H 15 ClN4[M+H] + : 359.1063, found 359.1068.

[0068] Example 14 1-(4-methylbenzyl)-2-(1 H -indol-5-yl)-1 H -imidazo[4,5- b Preparation of pyridine (13f) 1-(4-methylbenzyl)-2-(1-bromomethyl-4-chlorobenzene) was prepared according to the method of Example 13 instead of 1-bromomethyl-4-methylbenzene. H -indol-5-yl)-1 H -imidazo[4,5- b Pyridine, yield 80%. The structural formula of compound 13f is: .

[0069] The relevant data is as follows: mp: 258-259 ℃; 1 H NMR (500 MHz, DMSO- d 6) δ 11.44 (s, 1H), 8.41 (dd, J = 4.7, 1.1 Hz, 1H), 7.99 (s, 1H), 7.83 (dd, J = 8.0, 1.2 Hz, 1H),7.60 – 7.44 (m, 3H), 7.21 (dd, J = 8.0, 4.8 Hz, 1H), 7.09 (d, J = 7.9 Hz, 2H), 6.92 (d, J = 8.0 Hz, 2H), 6.54 (s, 1H), 5.61 (s, 2H), 2.22 (s, 3H). 13 C NMR (126MHz, DMSO- d 6) δ 156.97, 155.27, 143.84, 136.46, 133.44, 129.12, 127.96, 127.27,126.68, 125.93, 121.93, 121.33, 119.80, 118.68, 117.27, 111.58, 101.73,48.35, 47.30, 20.34. ESI-HRMS: m / z calcd. for C 22 H 18 N4[M+H] + : 339.1610, found339.1614.

[0070] Example 15 1-(4-trifluoromethylbenzyl)-2-(1 H -indol-5-yl)-1 H -imidazo[4,5- b Preparation of pyridine (13g) 1-(4-trifluoromethylbenzyl)-2-(1-bromomethyl-4-chlorobenzene) was prepared according to the method of Example 13, instead of 1-bromomethyl-4-trifluoromethylbenzene. H -indol-5-yl)-1 H -imidazo[4,5- b Pyridine, yield 87%. The structural formula of compound 13g is: .

[0071] The relevant data is as follows: mp: 261-262 ℃; 1 H NMR (500 MHz, DMSO- d 6) δ 11.45 (s, 1H), 8.45 (dd, J = 4.7, 1.4 Hz, 1H), 7.97 (d, J = 0.7 Hz, 1H), 7.87 (dd, J = 8.0, 1.5Hz, 1H), 7.67 (d, J = 8.2 Hz, 2H), 7.56 (d, J = 8.4 Hz, 1H), 7.51 – 7.46 (m,2H), 7.27 – 7.21 (m, 3H), 6.55 – 6.52 (m, 1H), 5.78 (s, 2H). 13 C NMR (126 MHz, DMSO- d 6) δ 157.34, 155.36, 144.31, 141.52, 136.71, 128.25, 128.04, 127.56,126.99, 125.79, 125.18, 123.01, 122.09, 121.61, 119.71, 119.00, 117.83,111.94, 102.05, 47.42. ESI-HRMS: m / z calcd. for C 22 H 15 F3N4[M+H] + : 393.1327, found 393.1331.

[0072] Example 16 The antitumor proliferative activity of the compounds in Examples 1-15 was determined using the CCK8 assay. The specific method is as follows: CCK8 assay was performed on HCT-116 (human colorectal cancer cells), NCM-460 (human colon cells), HGC-27 (human gastric cancer cells), A549 (human lung cancer cells), HepG-2 (human liver cancer cells), MDA-MB-231 (human breast cancer cells), GES-1 (human normal gastric mucosal epithelial cells), and MCF-10A (human normal breast epithelial cells) cells to evaluate the antiproliferative effects of all or some of the compounds, thereby selecting the preferred compounds.

[0073] Cell thawing was performed by removing the cryovials from the liquid nitrogen container and placing them in a 37°C water bath, gently shaking to thaw them. After thawing, the cell suspension was quickly transferred to a 5 mL centrifuge tube containing 2 mL of complete culture medium, mixed by pipetting, and centrifuged at 1000 rpm for 5 min. The lower cell pellet was retained, and the cells were resuspended in 4 mL of fresh complete culture medium. The suspension was then poured evenly into culture flasks and placed in a constant temperature incubator at 37°C, 5% CO2, and saturated humidity. The next day, cell adhesion was observed, and fresh culture medium was used to remove residual cryovial solution and dead cells that had not adhered.

[0074] When cells are passaged and the cell density reaches 70% to 80%, discard the original culture medium and gently add 2 mL of phosphate-buffered saline (PBS) along the cell wall, then gently wash twice. During digestion, add 1 mL of trypsin digestion solution to cover the cell surface. When cells begin to detach from the flask wall under a microscope, add 2 mL of complete culture medium to stop the digestion reaction. Gently blow the bottom of the flask with a pipette to transfer the suspension to a 5 mL centrifuge tube, centrifuge at 1000 r / min for 5 min, discard the supernatant, resuspend the cells in an appropriate amount of fresh culture medium, and retain the cell suspension in the original culture flask at a 1:3 ratio. Add 4 mL of fresh culture medium and place in an incubator.

[0075] For cell culture, first prepare 96-well plates by adding 200 μL of PBS to each well in the outermost and seventh column. The cell preparation process is the same as for passage: centrifuge the digested cells, remove the supernatant, and add 1 mL of fresh culture medium to the pellet to resuspend the cells. Count the cells in the suspension. Based on the cell proliferation rate, take an appropriate number of cells and mix them thoroughly with fresh culture medium in a sample loading well to form a homogeneous cell suspension. Add 100 μL of the cell suspension to each well of the 96-well plate, gently tap the plate wall to mix, and incubate in a cell culture incubator for 24 h until the cells adhere and grow, then proceed with further treatment.

[0076] For drug addition, the test compound and positive control drug YC-1 were dissolved in DMSO to prepare stock solutions with a concentration of 33333.33 μM, which were stored at -20 ℃ for later use. After incubation for 24 h, the original culture medium in the 96-well plates was discarded, and different concentration gradients of drug-containing culture medium were added sequentially, 200 μL per well. The highest drug concentration was 100 μM, and serial dilutions were performed at 1 / 2 folds, resulting in a total of 8 concentration gradients. Each drug treatment was performed in 3 replicates, and a medium containing 3% DMSO was set up as a negative control. According to the experimental design, after drug addition, the 96-well plates were placed in either a normoxic incubator (21% O2) or a hypoxic incubator (1% O2) for further incubation.

[0077] After 48 h of drug treatment, the drug-containing culture medium in each well was aspirated, and 100 μL of culture medium containing 10% CCK-8 solution was added. The plate was then incubated in an incubator for 1 h. After incubation, the 96-well plate was placed on a shaker and shaken in the dark for 3 min. The absorbance (OD value) of each well was then measured at a wavelength of 450 nm.

[0078] Inhibition rate = (OD value of negative control group - OD value of experimental group) / (OD value of negative control group - OD value of blank group) × 100% The inhibition rate of drug growth on each cell type at different concentrations was calculated using the above formula, and the half-maximal inhibitory concentration (IC50) of each drug was also calculated. 50 The obtained data were statistically analyzed using GraphPad Prism 8.0.2 software. To ensure the reliability of the experimental results, all operations were independently repeated three times. The results are shown in Tables 1, 2, and 3.

[0079] Table 1. IC50 of the compounds on HCT-116 cells 50 Value (μM)

[0080] a IC 50 The value represents the mean ± standard deviation (SD) of three repeated experiments.

[0081] b This represents the positive control drug.

[0082] Table 2. IC50 of compounds on various tumor cells 50 Value (μM)

[0083] a, b are the same as Table 1.

[0084] Table 3. IC50 of compounds on normal cells 50 Value (μM)

[0085] a, b are the same as Table 1.

[0086] The results showed that under normoxic conditions, the first series of compounds (line 6) exhibited almost no significant antiproliferative activity against HCT-116 cells. Under hypoxic conditions, however, the first series of compounds showed good antiproliferative activity, with compound 6a showing an IC50 value of [missing information]. 50 The value was (4.55 ± 0.72) μM, indicating the best activity; the IC50 values ​​for compounds 6b and 6c were... 50The values ​​were (8.16 ± 1.65) μM and (8.76 ± 1.66) μM, respectively, which also showed a certain inhibitory effect.

[0087] Therefore, compounds 6a, 6b, and 6c were selected to further investigate their antiproliferative activity in various tumor cell lines. The results showed that compound 6a exhibited excellent antiproliferative activity and good selectivity in all four cell lines. Under hypoxic conditions, 6a showed an IC50 inhibitory effect on human gastric cancer cells HGC-27 and human triple-negative breast cancer cells MDA-MB-231. 50 The values ​​were (1.05 ± 0.25) μM and (2.09 ± 0.03) μM, respectively, showing a strong inhibitory effect. Although compounds 6b and 6c also had some activity, their overall activity was not as strong as that of 6a.

[0088] The above results indicate that these compounds exhibit significant selective inhibitory effects on tumor cells under different oxygen environments, with significantly enhanced activity under hypoxic conditions. Simultaneously, the compounds show moderate toxicity to normal human colon cells, suggesting a promising safety window.

[0089] In comparison, the second series of compounds showed relatively low overall antiproliferative activity against HCT-116 cells.

[0090] Example 17 Cell colony formation assay to determine the antiproliferative effect of the compound in Example 1 MDA-MB-231 cells were digested with trypsin to prepare a single-cell suspension. After counting and adjusting the cell density, the cells were stored at 5 × 10⁶ cells per well. 4 Cells were seeded into six-well plates. After 24 h of culture at 37 ℃ and 5% CO2, and once the cells had fully adhered, drug intervention was initiated. Experimental groups included a blank control, a positive control, and treatment groups with different concentrations of the compound: the positive control group received 1 μM YC-1, while the compound treatment groups received 1, 2, and 4 μM compound 6a, respectively. Each group received the corresponding concentration of drug-containing medium prepared in DMEM containing 10% fetal bovine serum. The six-well plates were continuously cultured in a hypoxic incubator (1% O2, 5% CO2, 37 ℃) to simulate the hypoxic state of the tumor microenvironment.

[0091] After culture, the culture medium in the well plate was aspirated, and an appropriate amount of PBS was added to each well, followed by two gentle washes. Then, 500 μL of 4% paraformaldehyde fixative was added to each well, and the plate was fixed at room temperature for 15 min. After discarding the fixative, the plate was washed twice again with PBS, and 500 μL of 0.1% crystal violet staining solution was added to each well, and the plate was stained at room temperature for 30 min. After staining, the staining solution was removed, and the plate was gently washed with PBS until the background was clear, and then air-dried at room temperature. The six-well plate was observed under an inverted microscope, and the number of cell clones in each well was counted (a clone containing more than 50 cells was considered one clone). The colony formation rate was calculated to evaluate the inhibitory effect of compound 6a on the colony formation ability of MDA-MB-231 cells under hypoxic conditions.

[0092] Experimental results are as follows Figure 1 As shown, compound 6a exhibited a significantly stronger inhibitory effect on the clonogenic ability of MDA-MB-231 cells than the lead compound YC-1, and this effect was clearly concentration-dependent.

[0093] Example 18 Scratch assay was used to evaluate the effect of the compound in Example 1 on the migration ability of tumor cells.

[0094] MDA-MB-231 cells were collected, the culture medium was discarded, and the cells were gently washed with PBS. Then, an appropriate amount of trypsin digestion solution was added, and the cells were digested at 37 °C. When the cells gradually became rounded, DMEM medium containing 10% FBS was immediately added to terminate the digestion reaction. The cells were then gently pipetted, centrifuged to collect them, and resuspended in fresh culture medium. Cells were then divided into groups of 3 × 10⁶ cells per well. 5 Cells were seeded at a density of 1000 cells per well in 6-well plates and cultured in DMEM medium containing 10% fetal bovine serum at 37 °C and 1% CO2 for 24 h.

[0095] Using a 200 μL sterile pipette tip, draw straight lines perpendicular to the bottom of the well plate at a uniform speed and smoothly. Gently wash the well plate twice with PBS. Under a microscope, select a fixed position and record the initial scratch width. The experiment included a blank control group, a positive control group, and treatment groups with different concentrations of the compound: the positive control group was treated with 1 μM YC-1, and the compound treatment groups were treated with compound 6a at final concentrations of 1, 2, and 4 μM, respectively. All groups were maintained in DMEM medium containing 10% fetal bovine serum. After culturing for 24 h, the cells were removed, gently washed with PBS, and the scratch width was recorded again at the same location.

[0096] The width of scratches in each group was measured using image analysis software, and the cell migration rate was calculated to evaluate the effect of compound 6a on the migration ability of MDA-MB-231 cells.

[0097] The results are as follows Figure 2The results showed that compound 6a was superior to YC-1 in inhibiting tumor metastasis, and this effect was significantly concentration-dependent.

[0098] Example 19 The binding affinity of the compound from Example 1 to HIF-1α and its effect on protein stability were investigated using conventional Western blotting and thermal migration assay (CETSA).

[0099] The specific procedure for conventional Western blotting of proteins is as follows: Protein sample extraction and preparation: Cells in the logarithmic growth phase were seeded at a predetermined density in culture dishes and incubated at 37 ℃ in a 5% CO2 incubator for 48 h. The culture dishes were then placed on ice, and the culture medium was aspirated using a pipette. 2 mL of pre-chilled phosphate-buffered saline (PBS) was added, and the cells were gently washed twice. 150 μL of RIPA high-efficiency lysis buffer was added to the culture dishes, and lysis was performed on ice for 30 min. Adherent cells were scraped off and collected in 1.5 mL centrifuge tubes. The tubes were centrifuged at 14000 rpm for 15 min at 4 ℃. The supernatant was transferred to a new centrifuge tube to obtain the total protein extract.

[0100] Protein concentration determination by BCA method: The working solution was prepared according to the BCA protein quantification kit instructions, and a concentration gradient standard solution was prepared using bovine serum albumin (BSA) standard. 20 μL PBS was used as a blank control; 5 μL PBS was added to each blank control well, and 5 μL of the protein sample to be tested and different concentrations of protein standard were added to the remaining wells. 200 μL of BCA working solution was added to each well, mixed well, and incubated at 37 ℃ for 30 min. The absorbance values ​​of each well were measured, and a standard curve was plotted based on the standard concentration and absorbance.

[0101] Protein denaturation and sample preservation: Take the remaining protein sample and add 5× protein loading buffer at a volume ratio of 4:1. Mix thoroughly and heat in a 95 ℃ metal bath for 10 min. The prepared protein sample can be used immediately for electrophoresis or aliquoted and stored at -80 ℃ for long-term use.

[0102] SDS-PAGE gel preparation: Based on the target protein molecular weight, prepare an 8% separating gel according to the SDS-PAGE gel kit instructions. Pour the separating gel into the gaps between the glass plates to 1.5 cm from the top edge of the short glass plate. Add distilled water for liquid sealing and let stand at room temperature for 2 h. Pour off the supernatant distilled water and blot dry with filter paper. Prepare an 8% stacking gel and pour it into the gaps between the glass plates until full. Quickly insert a comb and let stand at room temperature for 1 h.

[0103] Electrophoresis: Insert the prepared gel into the electrophoresis tank, add sufficient electrophoresis buffer, and pull the comb vertically upwards. Take an equal amount of pre-stained protein marker and add it to the sample well. Set the voltage to 80 V and electrophoresis for 30 min. After the sample enters the separating gel, adjust the voltage to 120 V and continue electrophoresis until the protein marker bands are fully separated.

[0104] Transfer: Wet transfer was used. Pry open the electrophoresis glass plate and transfer the gel to transfer buffer. Cut a 0.45 μm PVDF membrane to match the gel size, activate it by soaking in methanol for 5 s, and then equilibrate the membrane, filter paper, and sponge pad in transfer buffer for 5 min. Place the sponge pad, filter paper, gel, PVDF membrane, filter paper, and sponge pad in the order from negative electrode (black) to positive electrode (white), ensuring no air bubbles remain between each layer. Place the transfer clamp in the electrophoresis tank, add transfer buffer, set the current to a constant 200 mA, and transfer for 1 h. After transfer, remove the PVDF membrane and mark the electrophoretic direction and protein side with a corner cut at the appropriate location. Blocking and Antibody Incubation: The PVDF membrane was washed with TBST buffer and placed in 5% skim milk blocking solution. It was blocked by shaking at room temperature for 2 hours. The membrane was then washed three times with TBST for 5 minutes each time. Primary Antibody Incubation: The primary antibody against the target protein was diluted 1:1000 with primary antibody dilution buffer. The PVDF membrane and the diluted primary antibody were placed together in an incubation chamber and reacted overnight at 4°C with shaking. The primary antibody was recovered the next day, and the membrane was washed three times with TBST (5 minutes each time). The secondary antibody was diluted 1:10000, and the membrane was immersed in the secondary antibody working solution and incubated on a shaker at room temperature for 1 hour. Finally, the membrane was washed three more times with TBST for 5 minutes each time.

[0105] Development and Image Acquisition: ECL developer solution A and solution B were prepared fresh each time at a 1:1 ratio, mixed thoroughly, and then applied to the surface of the PVDF membrane. The membrane was then placed in a chemiluminescence imaging system for detection, and the developed images were saved. ImageJ software was used to analyze the grayscale values ​​of the Western blot bands. The obtained data were statistically processed using GraphPad Prism 8.0.2 software, and bar charts were plotted. Experimental results are expressed as mean ± standard deviation. Results are as follows... Figure 3 The results of C and D indicate that compound 6a can significantly inhibit hypoxia-induced HIF-1α protein accumulation, and the inhibitory effect is clearly concentration-dependent, which can effectively antagonize the protein accumulation of HIF-1α under hypoxia.

[0106] The Cell Thermal Migration Assay (CETSA) method is as follows: Sample preparation and drug treatment: Total protein was extracted, and the protein concentration was determined using the BCA method and adjusted to be consistent. The protein samples were divided into two groups: the compound treatment group and the negative control group (DMSO), with a volume of 1.5 mL in each group. 1.5 μL of the test compound 6a (100 μmol) and an equal volume of DMSO were added to each group, and the mixture was incubated at room temperature for 30 min to allow the compound to fully react with the protein.

[0107] Temperature gradient treatment: The compound treatment group and the DMSO control group samples were each divided into 8 equal portions and transferred to 0.2 mL PCR tubes, with each tube containing approximately 150 μL. Eight heating temperature gradients were set: 37 ℃, 42 ℃, 47 ℃, 52 ℃, 57 ℃, 62 ℃, 67 ℃, and 72 ℃. The PCR tubes were placed in a gradient PCR instrument or a metal bath and heated for 3 min. After heating, the samples were removed, cooled to room temperature for 3 min, and then immediately placed on ice.

[0108] Isolation of heat-denatured proteins: The heat-treated samples were placed in a 4 ℃ low-temperature centrifuge and centrifuged at 20000×g for 20 min. After centrifugation, the supernatant was collected and its volume was recorded.

[0109] Western blot analysis: Take equal volumes of supernatant from each temperature point, add 5× loading buffer at a ratio of 4:1, mix well, and heat at 95 °C for 10 min. Subsequent steps include SDS-PAGE electrophoresis, membrane transfer, blocking, primary antibody incubation, secondary antibody incubation, and development (specific procedures are the same as for conventional Western blotting of proteins) to detect the relative content of the target protein at each temperature condition.

[0110] Data analysis: ImageJ software was used to perform grayscale analysis on the Western blot bands at each temperature point. Using the grayscale value of the 37℃ treatment group as a reference, the relative content of soluble protein at each temperature point was calculated. GraphPad Prism 8.0.2 software was used to plot the protein thermal melting curves.

[0111] The results are as follows Figure 3 A and B in the figure indicate that the combination of compound 6a with HIF-1α effectively enhances its thermal stability, increasing the Tm value of HIF-1α by about 6-8 °C, suggesting a direct interaction between the two.

[0112] Example 20 Experimental investigation on reactive oxygen species (ROS) to investigate whether the inhibitory effect of the compound in Example 1 on MDA-MB-231 cells is related to oxidative stress.

[0113] MDA-MB-231 cells in logarithmic growth phase were harvested, digested with trypsin, counted, and the cell density was adjusted to 3 × 10⁶ cells per well. 5Cells were evenly seeded at a density in six-well plates, with 2 mL of culture medium added to each well. The plates were then incubated in a hypoxic incubator at 37 °C and 1% O2 for 24 h. The original culture medium was removed, and fresh complete culture medium containing different concentrations of compound 6a was added to each well sequentially. The final concentration gradient of compound 6a was set at 0, 1, 2, and 4 μM, with the 0 μM group serving as a hypoxic control. Each concentration group was configured in triplicate. After 24 h of drug treatment, the drug-containing culture medium was discarded, and each well was gently washed twice with 1 mL of phosphate-buffered saline (PBS).

[0114] Intracellular ROS levels were detected using the DCFH-DA fluorescent probe method. The DCFH-DA probe was diluted 1:1000 to the working concentration using serum-free medium, and 500 μL of this dilution was added to each well. The cells were incubated at 37 ℃ in the dark for 30 min. After incubation, the working solution was removed, and each well was washed twice with 1 mL of PBS. Green fluorescence images of each group of cells were observed and acquired using a cell imaging system with an excitation wavelength of 488 nm.

[0115] The results are as follows Figure 4 As shown, compound 6a can induce ROS accumulation in MDA-MB-231 cells in a concentration-dependent manner.

[0116] Example 21 Apoptosis assay: The effect of the compound in Example 1 on cell apoptosis was detected by flow cytometry.

[0117] After digestion and counting of MDA-MB-231 cells with good cell morphology, they were divided into groups of 3 × 10⁶ cells per well. 5 Cells were seeded in six-well plates and cultured at 37 °C and 1% O2 for 24 h to allow them to adhere. The original culture medium was aspirated, and fresh complete culture medium containing different concentrations of compound 6a was added to each well, with concentration gradients of 0, 1, 2, and 4 μM, and three replicates per group. After 24 h of incubation, the culture medium from each well was collected for later use. Subsequently, an appropriate amount of EDTA-free trypsin was added to each well, and digestion was carried out at room temperature for approximately 1-2 min. When the cells became rounded and detached from the wells by gently tapping, digestion was stopped with the collected original culture medium from the previous step, and the cells were gently pipetted to mix. The entire cell suspension was then transferred to centrifuge tubes.

[0118] Centrifuge tubes were placed in a centrifuge and centrifuged at 1500 rpm for 5 min. The supernatant was discarded, and the cell pellet was collected. The cells were resuspended in 2 mL of PBS buffer and centrifuged again at 1500 rpm for 5 min. The supernatant was discarded. 100 μL of pre-prepared Annexin V-FITC binding working solution was added to each tube. After gentle pipetting, 10 μL of Annexin V-FITC fluorescent dye and 5 μL of propidium iodide (PI) staining solution were added, and the mixture was incubated at room temperature in the dark for 15 min. PBS buffer was then added to each tube to bring the total volume to 500 μL, and the mixture was gently mixed. The prepared samples were stored on ice in the dark and analyzed by flow cytometry within 1 h. The apoptosis rate induced by different concentrations of compound 6a was analyzed by fluorescence signal analysis.

[0119] The results are as follows Figure 5 This indicates that compound 6a can induce apoptosis in MDA-MB-231 cells in a concentration-dependent manner.

[0120] Example 22 Physicochemical properties were determined, and computer-aided drug design methods were used to predict the physicochemical properties of the compounds in Example 1.

[0121] First, the two-dimensional chemical structure of compound 6a was drawn in ChemDraw 21.0 software. The drawn structure was then converted to a Simplified Molecular Linear Input Specification (SMILES) string using the software's built-in structure conversion function. The obtained SMILES string was then input into the SwissADME online calculation platform (http: / / www.swissadme.ch / ). Based on the molecular topology and empirical parameters, the platform calculated and output the following parameters: number of hydrogen bond donors, number of hydrogen bond acceptors, number of rotatable bonds, lipid-water partition coefficient (CLogP), molar refractive index (MR), and topological polar surface area (TPSA). All parameters were automatically calculated and generated by the platform, and the results are shown in Table 4.

[0122] Table 4. Physicochemical properties of compound 6a

[0123] Overall, compound 6a exhibits good drug-like properties and membrane permeation potential, and its physicochemical properties basically meet the basic requirements for drug development.

[0124] Example 23 In vivo antitumor activity experiments were conducted using the MDA-MB-231 xenograft nude mouse model to evaluate the in vivo antitumor activity of the compounds in Example 1.

[0125] Four-week-old male BALB / c-nu nude mice were used in the experiment and housed in a specific pathogen-free (SPF) animal room for one week of acclimatization.

[0126] A triple-negative breast cancer tumor-bearing model was established by digesting and counting logarithmically growing MDA-MB-231 cells, resuspending them in PBS, and adjusting the cell density to 5 × 10⁻⁶. 8 Cells / mL. 0.1 mL of cell suspension was subcutaneously injected into the right axilla of each nude mouse. The average tumor volume reached approximately 100 mm. 3 Mice were randomly divided into 5 groups (n=5): a negative control, a positive control, and groups with different concentrations of the test compound. Each group received the drug via intraperitoneal injection every 2 days for 14 consecutive days, with a dosage of 10 mL / kg. The control group received an equal volume of solvent. During the experiment, mice were weighed every 2 days using an electronic balance, and the long diameter (L) and short diameter (W) of the tumor were measured using calipers. The tumor volume (TV) was calculated using the formula: "Tumor volume (TV) = 0.5 × L × W". 2 "The tumor volume was calculated and the tumor growth curve was plotted. 24 h after the end of drug administration, the mice were euthanized by cervical dislocation, the tumor tissue was completely dissected, the tumor weight was measured using a precision electronic balance, and the tumor inhibition rate was calculated."

[0127] The results are as follows Figure 6 As shown, compound 6a exhibited good in vivo antitumor activity in the MDA-MB-231 xenograft mouse model, while also demonstrating good tolerability and safety.

[0128] Example 24 Platelet aggregation inhibition experiment to investigate the effect of the compound in Example 1 on platelet aggregation function.

[0129] Fresh blood was collected from healthy volunteers via intravenous puncture into vacuum blood collection tubes containing heparin. The freshly collected whole blood was mixed thoroughly and divided into three groups. 250 μL of each group was placed in clean EP tubes, and 6a and the positive control drug YC-1 were added at concentrations of (50 μmol / L and 100 μmol / L), respectively. The mixtures were then incubated for 3 min. Platelet aggregation function was measured using an aggregometer with an equal amount of dimethyl sulfoxide as a negative control, and the experiment was repeated.

[0130] The results are as follows Figure 7 Compound 6a has an inhibitory effect on platelet aggregation, but the inhibitory effect is weaker than that of YC-1, thus improving its side effects.

[0131] Example 25 Molecular docking was used to investigate the binding mode of compound 6a from Example 1 with HIF-1α.

[0132] The crystal structure of HIF-1α (PDB ID: 4ZPR) was obtained from the RCSB Protein Data Bank. Water molecules, heteroatoms, and irrelevant ligands were removed using PyMOL to preserve the complete protein structure. The three-dimensional structure of compound 6a was optimized using PyMOL, and then molecular docking was performed between it and the pretreated target protein using AutoDock. The resulting three-dimensional binding pattern was visualized and analyzed using PyMOL.

[0133] Molecular docking results show that... Figure 8 , Figure 9 As shown, compound 6a is stably bound within the hydrophobic pocket of HIF-1α, located at the interface between the α and β chains. Hydrogen bonds are shown in yellow, while green lines represent p-π interactions. Specifically, the amino group of LYS155 in chain A forms two hydrogen bonds with the carbonyl oxygen and nitrogen atom of the benzimidazole ring. Furthermore, a p-π interaction is formed between the nitrogen atom of the imidazole ring in HIP166 (chain A) and the benzene ring. Simultaneously, the trifluoromethyl groups on the side chains participate in both electrostatic and hydrophobic interactions with LEU169 and GLU170 in chain A, and with HIP199 and VAL221 in chain B.

[0134] Those skilled in the art should understand that the discussion of any of the above embodiments is merely exemplary and is not intended to imply that the scope of protection of this application is limited to these examples; within the framework of this application, the technical features of the above embodiments or different embodiments can also be combined, the steps can be implemented in any order, and there are many other variations of different aspects of one or more embodiments of this application as described above, which are not provided in detail for the sake of brevity.

[0135] One or more embodiments in this application are intended to cover all such substitutions, modifications, and variations that fall within the broad scope of this application. Therefore, any omissions, modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of one or more embodiments in this application should be included within the protection scope of this application.

Claims

1. A benzimidazole derivative, characterized in that, The structural formula of the benzimidazole derivative is: , , or ; R1, R2, R3, R4, R5, R6, R7, R8, and R9 represent hydrogen, halogen, C1-3 alkyl, or trifluoromethyl, respectively.

2. The benzimidazole derivative according to claim 1, wherein R6, R7, R8, and R9 are H, the halogen is Cl or Br, and the alkyl group is methyl.

3. The benzimidazole derivative according to claim 2, wherein R1, R2, R3, R4, and R5 have only one substituent that is halogen, methyl, or trifluoromethyl, and the other substituents are H.

4. The benzimidazole derivative according to claim 3, wherein The structural formula of the benzimidazole derivative is: or R2is Cl, Br or methyl, R1, R3, R4, R5are H; or R1is Br, R2, R3, R4, R5are H.

5. The benzimidazole derivative as described in claim 4, characterized in that, The structural formula of the benzimidazole derivative is as follows: , or .

6. The benzimidazole derivative as described in claim 3, characterized in that, The structural formula of the benzimidazole derivative is as follows: , or .

7. A method for preparing a benzimidazole derivative as described in any one of claims 1-6, characterized in that, The preparation method is as follows: A compound having general formula A undergoes a nucleophilic substitution reaction with o-phenylenediamine in the presence of a solvent and an acid-binding agent to yield a compound having general formula C. Compounds having the general formula C react with cyanogen bromide in a solvent to give compounds having the general formula D; The above-mentioned compound is obtained by reacting a compound having general formula D with a compound having general formula E in the presence of a solvent and an acid-binding agent; The structural formula of the compound of general formula A is The structural formula of the compound with general formula C is The structural formula of the compound with general formula D is The structural formula of the compound with general formula E is: ; The preparation method is as follows: 1H-benzo[d]imidazol-2-carboxylic acid reacts with a solvent and an acid-binding agent to form an active ester intermediate B; Active ester intermediate B reacts with a compound having general formula C in the presence of a solvent to generate a compound having general formula D; The above-mentioned compound is obtained by reacting a compound having general formula D with a compound having general formula E in the presence of a solvent, an acid-binding agent, and a catalyst. The structural formula of active ester intermediate B is as follows: The structural formula of the compound with general formula C is The structural formula of the compound with general formula D is: The structural formula of the compound with general formula E is ; The preparation method is as follows: Using 3-nitropyridine-2-amine and a compound having general formula B as raw materials, a compound having general formula C was obtained under the action of a solvent, an acid-binding agent, and a catalyst. Compounds with general formula C undergo reduction reactions in the presence of solvents and catalysts to yield compounds with general formula D; Compounds of general formula D undergo a condensation reaction with 1H-indole-5-carboxaldehyde in the presence of a solvent to give compounds of general formula F. The above-mentioned compounds are obtained by reacting compounds having the general formula F with solvents and catalysts; The structural formula of the compound of general formula B is The structural formula of the compound with general formula C is The structural formula of the compound with general formula D is The structural formula of compounds with general formula F is ; The preparation method is as follows: A compound having general formula B undergoes a substitution reaction with 2-nitropyridine-3-amine in the presence of a solvent, an acid-binding agent, and a catalyst to yield a compound having general formula C. Compounds with general formula C undergo reduction reactions in the presence of solvents and catalysts to yield compounds with general formula D; Compounds of general formula D undergo a condensation reaction with 1H-indole-5-carboxaldehyde in the presence of a solvent to give compounds of general formula F. The above-mentioned compounds are obtained by reacting compounds having the general formula F with solvents and catalysts; The structural formula of the compound of general formula B is The structural formula of the compound with general formula C is The structural formula of the compound with general formula D is The structural formula of compounds with general formula F is .

8. Use of a benzimidazole derivative as described in any one of claims 1-6, characterized in that, The benzimidazole derivatives are used to prepare antitumor drugs.

9. The use as described in claim 8, characterized in that, The tumor is stomach cancer, colon cancer, colorectal cancer, breast cancer, liver cancer, or lung cancer.

10. The use as described in claim 8, characterized in that, The tumor is either stomach cancer or colon cancer.